Zentalis
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10275 Science Center Dr Ste 200, San Die...Phone Number
(212) 433-3791Website
www.zentalis.comRevenue
$26.9 MillionStock Symbol
ZNTLIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Zentalis
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing differentiated therapeutics targeting cancer pathways. Zentalis was founded in 2014 and is headquartered in New York City, New York.Explore more
Zentalis Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zentalis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Zentalis
Zentalis, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Zentalis has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Zentalis launches new products
Check out if Zentalis is spiking on competitors!
Funding: Get notified immidiatlly once Zentalis has new funding data
Click to see if Zentalis had a recent Job posting/layoffs
Earning: See what the market has to say on Zentalis recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Zentalis
Compare insights from companies similar to Zentalis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zentalis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zentalis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zentalis.
Zentalis financials insights
Gather financial insights about Zentalis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$165M
Series A
$20M
2021
Share Placement
$150.4M
Series B
$75M
Zentalis Tech Stack
A closer look at the technologies used by Zentalis
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Events, Medical Research, Pharmaceuticals
Open Position
Zentalis News & Media
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share. The total gross proceedZentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, preZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent corporate, regulatory and clinical progress and upcoming expected milestones.Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on August 3, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 84,000 shares of the Company’s common stock to two (2) newl
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zentalis
Sign Up For FreeTo access detailed company insights
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing differentiated therapeutics targeting cancer pathways. Zentalis was founded in 2014 and is headquartered in New York City, New York.... Read More
